Taken together, our findings show that 2-O-Bn-InsP5 could lead to the development of distinct more selective (hence less toxic) therapeutic strategies by targeting specifically the PDK1/PLCγ1 complex formation at the plasma membrane and its downstream pathways that may lead to the development of novel drugs capable of selectively inhibiting the invasive potential of cancer cells. This evidence concerns the gene PLCG1 and cancer.